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Andrea Jydstrup
Mentor - Sheri Holmen
Despite major improvements in imaging, radiation, and surgery, the
prognosis for patients with Glioblastoma multiforme (GBM) remains clinically
challenging. New treatment strategies are badly needed to reduce the mortality
and morbidity associated with this disease. The resistance of these tumors to
conventional treatments makes GBM patients ideal candidates for molecularly
targeted therapies and several agents are currently being developed(1). Because
GBM is genetically heterogeneous, combination therapies or the use of
multikinase inhibitors are more likely to achieve the greatest therapeutic
benefit(2,3). However, genes that can be productively targeted for effective
therapies in patients remain to be identified. The overall objective of this project
was to better understand the signaling pathways driving cell survival so that new
targets can be identified in gliomas. These studies will lead to an increased
understanding of the proteins that are altered in this disease and should provide
promising opportunities to develop better treatment strategies based on specific
molecular targets.
Two parallel pathways, which are both activated in GBM, converge on
downstream survival signaling cascades. Studies have demonstrated that
blocking only one pathway often leads to a transient response (e.g., delayed time
to progression), but tumors eventually progress(4). More effective therapies are
likely to be those that inhibit more than one target or pathway(5). Targeting antiapoptotic Bcl-2 proteins in combination with RAS/MAPK or AKT/mTOR inhibition
is a rationale approach.
To determine if inhibiting both the RAS/MAPK and AKT/mTOR pathways
in combination results in increased apoptosis in glioma cells, I compared the
level of apoptosis in cells treated with each inhibitor alone and in combination.
Treatment of glioma cells with a MEK inhibitor in combination with a PI(3)K
inhibitor has not previously been reported and therefore represents a new
approach in the field. We already know that just inhibiting RAS/MAPK or
AKT/mTOR alone results in cell cycle arrest but not death. I tested the effect on
cell death when combining the inhibitors of both pathways, and saw an increase
in cell death. I determined the growth inhibitory and apoptotic sensitivity of
several human glioma cell lines to inhibition of both RAS/MAPK and AKT/mTOR
pathways. Due to the heterogeneous nature of GBM, I predicted and saw that
these cell lines display varying levels of sensitivity to MEK/PI(3)K inhibition.
These differences can then be used in the future to further define the
mechanism(s) by which the AKT and MAPK pathways mediate survival signaling
in glioma cells.
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Despite major improvements in imaging, radiation, and surgery, the prognosis for patients with
Glioblastoma multiforme (GBM) remains clinically challenging. New treatment strategies are badly
needed to reduce the mortality and morbidity associated with this disease. The resistance of these
tumors to conventional treatments makes GBM patients ideal candidates for molecularly targeted
therapies and several agents are currently being developed(1). Because GBM is genetically
heterogeneous, combination therapies or the use of multikinase inhibitors are more likely to achieve
the greatest therapeutic benefit(2,3). However, genes that can be productively targeted for effective
therapies in patients remain to be identified. The overall objective of this project was to better
understand the signaling pathways driving cell survival so that new targets can be identified in
gliomas. These studies will lead to an increased understanding of the proteins that are altered in this
disease and should provide promising opportunities to develop better treatment strategies based on
specific molecular targets.
Two parallel pathways, which are both activated in GBM, converge on downstream survival
signaling cascades. Studies have demonstrated that blocking only one pathway often leads to a
transient response (e.g., delayed time to progression), but tumors eventually progress(4). More
effective therapies are likely to be those that inhibit more than one target or pathway(5). Targeting
anti-apoptotic Bcl-2 proteins in combination with RAS/MAPK or AKT/mTOR inhibition is a rationale
approach.
To determine if inhibiting both the RAS/MAPK and AKT/mTOR pathways in combination results
in increased apoptosis in glioma cells, I compared the level of apoptosis in cells treated with each
inhibitor alone and in combination. Treatment of glioma cells with a MEK inhibitor in combination with
a PI(3)K inhibitor has not previously been reported and therefore represents a new approach in the
field. We already know that just inhibiting RAS/MAPK or AKT/mTOR alone results in cell cycle arrest
but not death. I tested the effect on cell death when combining the inhibitors of both pathways, and
saw an increase in cell death. I determined the growth inhibitory and apoptotic sensitivity of several
human glioma cell lines to inhibition of both RAS/MAPK and AKT/mTOR pathways. Due to the
heterogeneous nature of GBM, I predicted and saw that these cell lines display varying levels of
sensitivity to MEK/PI(3)K inhibition. These differences can then be used in the future to further define
the mechanism(s) by which the AKT and MAPK pathways mediate survival signaling in glioma cells.

A high-throughput system (SuperArray CASE ELISA) was used
to determine the optimal concentrations of inhibitors to decrease
phosphorylation in the two signaling cascades after a 48 hour
(BEZ235) and 72 hour (CI-1040) treatment period.
Western Blots were used to verify the inhibition of phosphorylated
proteins in the pathway (P-ERK, P-AKT, P-p70s6K, and P-MEK)
and reprobed for total protein and α-tubulin. Flow cytometry was
used to determine cell cycle arrest and apoptosis.
The two inhibitors used were CI-1040 (Pfizer), which is a 2nd
generation MEK inhibitor, and BEZ235 (Novartis), which is a Class I
phosphatidylinositol-3-kinase (PI3K) tyrosine kinase inhibitor.
Inhibitors were used alone and in combination to compare levels
of phosphorylation and apoptosis in the six human GBM cell lines
SF-268, SF-295, SF-538, SNB19, SNB75, and U251.

Sensitivity:

THE EFFECTS OF HOST PHYSIOLOGICAL CONDITIONS ON THE EXPRESSION OF ICSP IN SHIGELLA FLEXNERI

Shigella flexneri is a gram-negative bacterium capable of causing diarrhea and dysentery known as shigellosis. It is
estimated there are 167.4 million shigellosis episodes throughout the world each year causing 1.1 million deaths. Shigella
invades cells in the lower intestine through an induced phagocytosis. Once in the cytoplasm, bacteria move from one cell
Inhibitors
used:
to another using actin-based motility. The ShigellaCI-1040
outer
membrane protease IcsP regulates actin-based motility and celland BEZ 235
to-cell spread by cleaving the actin assembly protein IcsA from the bacterial cell surface. We hypothesize that IcsP may
serve additional functions during infection. By examining which environmental signals trigger icsP expression, we aim to
identify other regions of the body where IcsP might function. Shigellae are exposed to an array of environmental
conditions
in the body. We examined the presence of bile salts, low pH, and anaerobic conditions in this study.
BACKGROUND
Glioma
Grade and Prognosis
Expression
of icsP and IcsP levels were assessed in bacteria grown under each of these physiological conditions using βGrade galactosidase
1: Pilocytic astrocytomas, Curable by surgery
assays and western blots, respectively.
RESULTS Growth of Shigella strains was reduced in the presence of
Very distinct from the other grades
Grade deoxycholate,
2: Survival can be as long as 10-15 years
a common bile salt, as compared to the control. In stationary growth phase, icsP expression increased
Grade 3: Anaplastic astrocytomas, 2-3 year survival
when the bacteria were grown in the presence of bile salts. Growth of Shigella in medium buffered at pH 5.5 was slightly
Grade 4: Glioblastoma multiforme (GBM)
GBMs make up ~50%
of all primary brain
tumors
elevated
(<10%
more
growth) when compared to bacteria grown in medium at pH 7.4. We also found that anaerobic
~21,800 new cases per year*
Average survival is ~12 months
conditions
negatively
impact
the growth of Shigella. Expression of icsP has not yet been measured
under this condition.
~13,070 deaths per year
CONCLUSIONS
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Western blots were performed on cell lysates from cells treated with the indicated inhibitors for 72 hours, with the BEZ235 being refreshed
every 24 hours. The results show that the CI-1040 inhibited p-ERK, while the BEZ235 compound inhibited p-p70s6k to varying degrees
between the cell lines, as predicted (red). Interestingly, an increase in phosphorylated ERK can be seen when treated with the PI(3)K inhibitor
(green), which corresponds to the negative regulation that AKT has on B-Raf, a protein upstream of ERK in the signaling cascade.

CI-1040
Noncompetitive inhibitor of MEK1

BEZ 235
Class I PI(3)K inhibitor

SNB19 Control (no treatment)
56.1%

SNB19 Combo (both treatments)

SF-295 Control (no treatment)

SF-295 Combo (both treatments)

53.8%

65.1%

53.7%

0.7%

For the CASE ELISA, a colorimetric determination system is used to
determine the relative amount of phosphorylated protein in cells. The lower
the O.D., the lower the amount of phosphorylated protein, and therefore the
pathways are less active and the cells are less able to proliferate.

13.3%

3.3%

15.7%

A flow cytometer (Guava) was used to determine cell apoptosis and G1 growth arrest to see if the inhibitors were killing the GBM tumor cells.
Although there wasn’t a large amount of apoptosis (sub G1= brown), there was a visible increase in cell death and cells present in the G1 phase
(pink) when comparing the control cells and cells treated with the combination of drugs. The green area represents S phase and the blue peak
represents G2/M phase in the cell cycle.

*CA Cancer J Clin 58:71-96 (2008)

Positron Emission Tomography (PET) Scan of GBM Tumor
www.mayoclinic.org/images/pet-tumor-bdy.jpg

AKT/mTOR and RAS/MAPK Signaling Cascades Active in GBM
72 hour treatment in RPMI media

Dose curve for CI-1040- determination of the relative concentration required to
inhibit phosphorylation of ERK (MAPK pathway). The dose curve shows that 10 µM

The main conclusion that can be drawn from these experiments is that the CI-1040 and BEZ235
compounds do inhibit their respective pathways, but there is something in the cell that is keeping the
combination of them from inducing complete apoptosis. Different concentrations may need to be used
in combination than the single agent studies indicated.
The data obtained also show significant “cross-talk” between the two pathways, which could
also be affecting the combination’s ability to work as effectively as expected. Specifically, an increase in
P-ERK can be seen when the PI(3)K is inhibited, which may be enough for the cells to survive. This
was apparent by both the Western blots and CASE ELISA studies (data not shown). The main objective
now will be to find ways to stop the feedback between the two pathways so that complete cell death can
be achieved.

FUTURE DIRECTIONS

appears to be the best concentration of CI-1040 to inhibit phosphorylation of proteins downstream
of MEK in the RAS/MAPK signaling cascade.

BEZ235

CI-1040

Different concentrations of inhibitors can be tested to see if higher concentrations are necessary
when combined. There are also newer generations of compounds being released that may hit their
targets more effectively and be more stable in the cell than the ones tested here.

The PI(3)K/mTOR
and RAS/MAPK
pathways are both
active in GBM and
engage in “crosstalk” via positive
and negative
regulation that
makes it very
difficult to inhibit
both pathways
simultaneously.

Other proteins known to be involved in apoptosis will be examined, like the anti-apoptotic Bcl-2
family members, including Bcl-2 and Bcl-xl. If these can be inhibited, cell death may be achieved
more fully.
siRNA will also be performed to completely knock out phosphorylated (activated) proteins. Some
possibilities to target include all three isoforms of Raf (A,B, and C) and PI(3)K, thus disabling the
pathways for cell survival.
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48 hour treatment in RPMI media

Dose curve for BEZ 235- determination of the relative concentration required to
inhibit phosphorylation of AKT (PI3K pathway). The dose curve shows that 0.1 µM of BEZ235
Modified from:
Sebolt-Leopold, J. S. & English, J. M. Mechanisms of drug
inhibition of signalling molecules. Nature 441, 457-62 (2006).

inhibits phosphorylation of proteins downstream of PI3K in the AKT/mTOR signaling cascade in most of the cell
lines. 0.1 µM was chosen over 1 µM because at a certain point, there is a risk of cytotoxicity unrelated to
apoptosis.
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